Patent ID: 7211383
Filing Date: 2007-05-01
Classification: C12Q

Abstract:
1. A method of assessing the advisabilitv that a human should apply a product comprising a skin protective agent, the method comprising assessing occurrence in the human's genome of at least three polymorphisms selected from the group consisting of i) a polymorphism manifested as occurrence of a codon encoding alanine at amino acid residue 9 of mitochondrial MnSOD; ii) a polymorphism manifested as occurrence of a codon encoding valine at amino acid residue 9 of mitochondrial MnSOD; iii) a polymorphism manifested as occurrence of a codon encoding isoleucine at amino acid residue 58 of mitochondrial MnSOD; iv) a polymorphism manifested as occurrence of a codon encoding thymine at amino acid residue 58 of mitochondrial MnSOD; v) a polymorphism manifested as occurrence of a codon encoding valine at amino acid residue 7 of cytoplasmic CZSOD; vi) a polymorphism manifested as occurrence of a codon encoding glutamic acid at amino acid residue 7 of cytoplasmic CZSOD; vii) a polymorphism manifested as occurrence of a codon encoding cysteine at amino acid residue 6 of cytoplasmic CZSOD; viii) a polymorphism manifested as occurrence of a codon encoding phenylalanine at amino acid residue 6 of cytoplasmic CZSOD; ix) a polymorphism manifested as occurrence of a cytosine residue at nucleotide residue-262 of the catalase gene; x) a polymorphism manifested as occurrence of a thymine residue at nucleotide residue-262 of the catalase gene; xi) a polymorphism manifested as occurrence of a codon encoding proline at amino acid residue 198 of hGPX1; xii) a polymorphism manifested as occurrence of a codon encoding leucine at amino acid residue 198 of hGPX1; xiii) a polymorphism manifested as occurrence of a codon encoding valine at amino acid residue 105 of GSTP1; xiv) a polymorphism manifested as occurrence of a codon encoding isoleucine at amino acid residue 105 of GSTP1; xv) a polymorphism manifested as occurrence of a cytosine residue at nucleotide residue 242 of the gene encoding NAD(P)H:quinone oxidoreductase; xvi) a polymorphism manifested as occurrence of a thymine residue at nucleotide residue 242 of the gene encoding NAD(P)H:quinone oxidoreductase; xvii) a polymorphism manifested as occurrence of a thymine residue at nucleotide residue 113 in exon 3 of the gene which encodes epoxide hydrolase; xviii) a polymorphism manifested as occurrence of a cytosine residue at nucleotide residue 113 in exon 3 of the gene which encodes epoxide hydrolase; xix) a polymorphism manifested as occurrence of an adenine residue at nucleotide residue -238 of the gene which encodes TNF-alpha; xx) a polymorphism manifested as occurrence of an adenine residue at nucleotide residue -308 of the gene which encodes TNF-alpha; xxi) a polymorphism manifested as occurrence of a cytosine residue at nucleotide residue 242 of the phox gene; xxii) a polymorphism manifested as occurrence of a thymine residue at nucleotide residue 242 of the phox gene; xxiii) a polymorphism manifested as occurrence of a 27 nucleotide residue repeat between nucleotide residues 5130 and 5511 of the gene encoding nitric oxide synthase; xxiv) a polymorphism manifested as non-occurrence of a 27 nucleotide residue repeat between nucleotide residues 5130 and 5511 of the gene encoding nitric oxide synthase; xxv) a polymorphism manifested as occurrence of an adenine residue at nucleotide residue -290 of the gene encoding cytochrome P450 (i.e., the polymorphism designated the CYP3A4 cytochrome P450 variant); xxvi) a polymorphism manifested as occurrence of a guanine residue at nucleotide residue -290 of the gene encoding cytochrome P450 (i.e., the polymorphism designated the CYP3A4 cytochrome P450 variant); xxvii) a polymorphism manifested as occurrence of a single guanine residue at nucleotide residue -1607 of the human gene encoding MMP-1; and xxviii) a polymorphism manifested as occurrence of a two consecutive guanine residues at a site including nucleotide residue-1607 of the human gene encoding MMP-1, wherein the advisability that a human should consume or apply the product is determined based on occurrence of the assessed polymorphisms.